Westmead Hospital

Researchers

• MBMichael J Bourke

Running trials

• Not yet recruiting

  Right Colon Enema to Improve Bowel Preparation Quality During Colonoscopy

  NCT07813013· Westmead Hospital· Source

• Recruiting

  A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

  NCT07735546· Phase 1· Umoja Biopharma· Source

• Not yet recruiting

  Baerveldt Versus Paul Study

  NCT07733453· Phase 4· University of Sydney· Source

• Recruiting

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· Phase 1/2· XYone Therapeutics, Inc· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  NCT07476287· Phase 2· Pfizer· Source

• Recruiting

  Intratumoral N17350 in Advanced Solid Tumors

  NCT07339176· Phase 1/2· Onchilles Pharma Inc· Source

• Recruiting

  A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

  NCT07536061· Phase 1· Sarepta Therapeutics, Inc.· Source

• Enrolling by invitation

  An Extension of SKY-0515 in Participants With Huntington's Disease

  NCT07537075· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

  NCT07197580· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  NCT07244263· Phase 2· Takeda· Source

• Recruiting

  A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  NCT07235293· Phase 2· Kahr Bio Australia Pty Ltd· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  NCT07226999· Phase 2/3· Pfizer· Source

• Recruiting

  A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

  NCT07255404· Phase 2· BioNTech SE· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease

  NCT06360939· Western Sydney Local Health District· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

• Recruiting

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· Phase 2· CSL Behring· Source

• Recruiting

  IDOV-Immune for Advanced Solid Tumors

  NCT06910657· Phase 1· ViroMissile, Inc.· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· Phase 3· Celgene· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Celcuity Inc· Source

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Daiichi Sankyo· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Active, not recruiting

  A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

  NCT06649695· Phase 2· European Myeloma Network B.V.· Source

• Recruiting

  Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea

  NCT07049744· XII Medical· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

• Recruiting

  Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

  NCT06782971· Clinical Hub for Interventional Research (CHOIR)· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Active, not recruiting

  Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

  NCT06873334· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

Showing 50 of 180.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer15 recruiting
• Colorectal cancer9 recruiting
• Melanoma9 recruiting
• Pancreatic cancer6 recruiting
• Gastric and oesophageal cancer5 recruiting
• Liver and biliary tract cancer5 recruiting
• Ovarian cancer5 recruiting
• Amyloidosis4 recruiting
• Huntington's disease4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Immune thrombocytopenia (ITP)4 recruiting
• Acute myeloid leukaemia3 recruiting
• Childhood cancers3 recruiting
• Chronic kidney disease3 recruiting
• Endometrial cancer3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Heart failure3 recruiting
• Myelodysplastic syndromes3 recruiting
• Prostate cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Antiphospholipid syndrome2 recruiting
• Atrial fibrillation2 recruiting
• Brain metastases2 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Cystic fibrosis2 recruiting
• Depression2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Head and neck cancer2 recruiting
• IgA nephropathy2 recruiting
• Kidney cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Parkinson disease2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• Ventricular tachycardia2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic stenosis1 recruiting
• Barrett's oesophagus1 recruiting
• Bladder cancer1 recruiting
• Bronchiectasis1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Fabry disease1 recruiting
• Glaucoma1 recruiting
• Hepatitis B1 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Nephrotic syndrome1 recruiting
• Neuroendocrine tumours1 recruiting
• Obstructive sleep apnoea1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

  NCT06940154· Phase 2· Connect Biopharm LLC· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of Artesunate

  NCT06853184· Phase 2· Amivas Inc.· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

  NCT06490445· Phase 2· Syqe Medical· Source

• Terminated

  Efficacy and Safety of HB-1 for Panic Disorder

  NCT06483789· Phase 2· HB BioTech, LLC· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Terminated

  A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

  NCT06194877· Phase 1· MapKure, LLC· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Respirion Pharmaceuticals Pty Ltd· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  NCT06272981· Biosense Webster, Inc.· Source

• Withdrawn

  A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

  NCT06153095· Phase 1/2· Lyell Immunopharma, Inc.· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Trevi Therapeutics· Source

• Completed

  A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

  NCT06064929· Phase 1· HI-Bio, A Biogen Company· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

  NCT06013969· Phase 4· LEO Pharma· Source

• Completed

  SBD121, a Synbiotic Medical Food for RA Management

  NCT06005220· Solarea Bio, Inc· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

• Terminated

  The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

  NCT04876651· Phase 3· Telix Pharmaceuticals (Innovations) Pty Ltd· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Terminated

  A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

  NCT05605522· Phase 1· 3B Pharmaceuticals GmbH· Source

• Recruiting

  Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

  NCT05518578· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Terminated

  Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

  NCT05667662· Phase 2· Pulmatrix Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Terminated

  A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT05505825· Phase 1/2· Akeso· Source

• Completed

  Study of ATH434 in Participants with Multiple System Atrophy

  NCT05109091· Phase 2· Alterity Therapeutics· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Amgen· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

  NCT02645149· Phase 2· Melanoma Institute Australia· Source

• Completed

  A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

  NCT04911751· Phase 2· KoBioLabs· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  Cochlear Implant With Dexamethasone Eluting Electrode Array

  NCT04750642· Cochlear· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Wave Life Sciences USA, Inc.· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· University of Calgary· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  RegoNivo vs Standard of Care Chemotherapy in AGOC

  NCT04879368· Phase 3· Australasian Gastro-Intestinal Trials Group· Source

Showing 50 of 74.

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma37 works · 21 trials
• Amyloidosis18 works · 6 trials
• Ventricular tachycardia17 works · 3 trials
• Cytomegalovirus infection11 works · 2 trials
• Cerebral palsy10 works · 0 trials
• Dystonia7 works · 0 trials
• Polycystic kidney disease7 works · 1 trial
• Hidradenitis suppurativa6 works · 3 trials
• Barrett's oesophagus4 works · 1 trial
• Neurofibromatosis type 14 works · 0 trials